Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

Rhea-AI Summary

Eyenovia, Inc. (Nasdaq: EYEN) announced positive results from the Phase 3 VISION-2 study of MicroLine for presbyopia, meeting primary and secondary endpoints with a significant improvement in visual acuity. The company plans to engage with the FDA on its regulatory path as a drug/device combination. Financial results for Q3 2022 showed a net loss of $7.3 million, up from $5.6 million in Q3 2021. Operating expenses rose 22% year-over-year. Eyenovia ended the quarter with $25.3 million in cash and equivalents. The company emphasizes key milestones expected in 2023.

Positive

• Positive results from VISION-2 study, achieving primary and secondary endpoints.
• Plan to meet with FDA for regulatory alignment on MicroLine.
• Operational cash balance of $25.3 million supports ongoing development.

Negative

• Net loss increased to $(7.3) million for Q3 2022, up from $(5.6) million in Q3 2021.
• Operating expenses rose by 22% year-over-year, indicating potential financial strain.

Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combination product

Company to host conference call and webcast today, November 10, at 4:30 pm ET

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the third quarter ended September 30, 2022.

Third Quarter 2022 and Recent Business Developments

• Announced that in a modified per-protocol analysis of evaluable patients, VISION-2 met its primary endpoint with a statistically significant proportion of MicroLine-treated subjects showing a ≥15-letter improvement in distance corrected near visual acuity (DCNVA) with less than a 5-letter loss in distance acuity versus placebo in low light conditions at two hours post-treatment. The study also achieved all secondary endpoints and the Company is planning to meet with the FDA as soon as practicable.
• Development partner Arctic Vision continues to enroll patients in its Phase 3 study of MicroLine (ARVN003) as a potential treatment for presbyopia in China. Arctic Vision anticipates completing the study in late 2023.
• Announced data at the 40^th Congress of the European Society Of Cataract and Refractive Surgeons (ESCRS) in September 2022 demonstrating that preserved drugs delivered with the Optejet act more like unpreserved drugs, reducing ocular stress and potentially avoiding long-term adverse events.
• Announced the appointment of Eyenovia’s former Chief Operating Officer, Michael Rowe, as the Company’s new Chief Executive Officer. Mr. Rowe was also appointed to Eyenovia’s Board of Directors.
• Announced that the Company’s new manufacturing facility in Redwood City, CA is now operational, and also announced the appointment of Bren Kern as Senior Vice President of Operations.
• Ended the third quarter of 2022 with approximately $25.3 million in total cash and cash equivalents, including $7.9 million of restricted cash.

Michael Rowe, Chief Executive Officer, commented, “Since our last quarterly update, we achieved a significant milestone with positive results from VISION-2, our second Phase 3 trial of MicroLine, a potential topical, on-demand therapeutic that we are developing as a temporary treatment for presbyopia. We are planning to meet with the FDA early next year followed by the manufacture of registration batches at our new, state-of-the-art facility in Redwood City, CA.”

“Our collaboration and license agreements with Bausch+Lomb and Arctic Vision are progressing nicely, and Arctic Vision continues to enroll patients in its own Phase 3 trial of MicroLine in China. This study, when complete in late 2023, is expected to add to the growing body of evidence demonstrating the safety and efficacy of MicroLine and Optejet. We continue to evaluate additional opportunities to partner or collaborate in other high value ophthalmic indications where the Optejet technology can be used to improve medical care.”

“We believe we have set the stage for achievement of multiple key milestones in 2023, and we will work tirelessly to sustain the momentum that we currently enjoy.”

Third Quarter 2022 Financial Review

For the third quarter of 2022, net loss was approximately $(7.3) million, or $(0.21) per share compared to a net loss of approximately $(5.6) million, or $(0.21) per share, for the third quarter of 2021.

Research and development expenses totaled approximately $3.9 million for the third quarter of 2022 as compared to $3.6 million for the third quarter of 2021, an increase of approximately 9.1%.

For the third quarter of 2022, general and administrative expenses were approximately $3.4 million, compared to $2.4 million for the third quarter of 2021, an increase of approximately 41.3%.

Total operating expenses for the third quarter of 2022 were approximately $7.2 million compared to $5.9 million for the third quarter of 2021. This represents an increase of approximately 22.0 %.

As of September 30, 2022, the Company’s cash and cash equivalents were approximately $25.3 million, including $7.9 million of restricted cash, as compared to $27.3 million as of December 31, 2021.

Conference Call and Webcast

The conference call is scheduled to begin at 4:30 pm ET today, November 10. Participants should dial 1-866-575-6539 (domestic) or 1-929-477-0448 (international) with the conference code 1600616. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About the VISION Trials

The VISION trials are Phase 3, double-masked, placebo-controlled, cross-over superiority trials that enroll participants with presbyopia. The primary endpoint is improvement in high-contrast binocular distance corrected near visual acuity in low light conditions. MicroLine is intended for the “on demand” improvement of near vision in people with presbyopia.

About MicroLine for Presbyopia

MicroLine (pilocarpine ophthalmic spray) is Eyenovia’s investigational pharmacologic treatment for presbyopia. Presbyopia, or farsightedness, is the non-preventable, age-related hardening of the lens, which causes a gradual loss of the eye’s ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the Company’s high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability. MicroLine has been licensed to Arctic Vision (Hong Kong) Limited in Greater China and South Korea.

About MicroPine for Progressive Myopia

MicroPine (atropine ophthalmic spray) is Eyenovia’s investigational, potentially first-in-class topical treatment for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. It has been developed for comfort and ease-of-use in children, and its microdose administration is designed to potentially result in low systemic and ocular drug exposure. MicroPine has been licensed to Bausch+Lomb, Inc. in the United States and Canada, and Arctic Vision (Hong Kong) Limited in Greater China and South Korea.

About Mydcombi™ for Mydriasis

Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation), which is targeted to improve the efficiency of the estimated 100 million office-based comprehensive eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. Developed as a micro-formulation for use without anesthetic, Eyenovia believes Mydcombi will help improve the efficacy, tolerability, and efficiency of pharmacologic mydriasis. Mydcombi has been licensed to Arctic Vision (Hong Kong) Limited in Greater China and South Korea.

About Optejet® and Microdose Array Print (MAP™) Therapeutics

Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We estimate the volume of ophthalmic solution administered with the Optejet is less than 20% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85% of the time after basic training in a variety of clinical settings compared to 40 – 50% historically seen with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.

About Eyenovia, Inc.

Eyenovia, Inc. (Nasdaq: EYEN) is an pre-commercial ophthalmic technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 and related economic disruptions on our supply chain, including the availability of sufficient components and materials used in our product candidates; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; our competitive position; and other risks described from time to time in the “Risk Factors” section of our filings with the U.S. Securities and Exchange Commission, including those described in our Annual Report on Form 10-K as well as our Quarterly Reports on Form 10-Q, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
Eyenovia
nlowe@eyenovia.com

EYENOVIA, INC.
Condensed Balance Sheets
	September 30,				December 31,
		2022				2021
	(unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	17,398,605			$	19,461,850
Restricted cash		7,875,000				7,875,000
Deferred clinical supply costs		1,871,096				-
License fee and expense reimbursements receivable		809,430				1,805,065
Prepaid expenses and other current assets		1,463,020				721,438
Total Current Assets		29,417,151				29,863,353
Property and equipment, net		1,342,657				1,271,225
Security deposits		200,153				132,539
Equipment deposits		445,530				391,941
Total Assets	$	31,405,491			$	31,659,058
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable	$	1,104,959			$	1,614,104
Accrued compensation		1,268,009				1,543,618
Accrued expenses and other current liabilities		1,384,803				845,719
Deferred rent - current portion		28,999				18,685
Notes payable		7,229,013				7,150,368
Total Current Liabilities		11,015,783				11,172,494
Deferred rent - non-current portion		60,540				19,949
Total Liabilities		11,076,323				11,192,443
Stockholders' Equity:
Preferred stock, $0.0001 par value, 6,000,000 shares authorized;
0 shares issued and outstanding as of September 30, 2022 and
December 31, 2021		-				-
Common stock, $0.0001 par value, 90,000,000 shares authorized;
35,525,689 and 28,426,616 shares issued and outstanding
as of September 30, 2022 and December 31, 2021, respectively		3,553				2,844
Additional paid-in capital		132,432,682				110,683,077
Accumulated deficit		(112,107,067	)			(90,219,306	)
Total Stockholders' Equity		20,329,168				20,466,615
Total Liabilities and Stockholders' Equity	$	31,405,491			$	31,659,058

EYENOVIA, INC.
Condensed Statements of Operations
(unaudited)
	For the Three Months Ended								For the Nine Months Ended
	September 30,								September 30,
		2022				2021				2022				2021
Operating Income
Revenue	$	-			$	-			$	-			$	4,000,000
Cost of revenue		-				-				-				(1,600,000	)
Gross Profit		-				-				-				2,400,000
Operating Expenses:
Research and development		3,876,876				3,552,068				11,176,326				11,559,364
General and administrative		3,353,352				2,372,999				10,362,907				6,914,481
Total Operating Expenses		7,230,228				5,925,067				21,539,233				18,473,845
Loss From Operations		(7,230,228	)			(5,925,067	)			(21,539,233	)			(16,073,845	)
Other Income (Expense):
Extinguishment of PPP 7(a) loan		-				463,353				-				463,353
Other income, net		70,277				11,728				96,580				48,880
Interest expense		(177,138	)			(119,212	)			(475,811	)			(202,407	)
Interest income		28,093				600				30,703				2,354
						-
Net Loss	$	(7,308,996	)		$	(5,568,598	)		$	(21,887,761	)		$	(15,761,665	)
Net Loss Per Share - Basic and Diluted	$	(0.21	)		$	(0.21	)		$	(0.67	)		$	(0.61	)
Weighted Average Number of Common
Shares Outstanding
- Basic and Diluted		34,631,774				26,053,532				32,778,551				25,773,098

FAQ

What are the results of Eyenovia's VISION-2 study for MicroLine?

The VISION-2 study showed that MicroLine met its primary endpoint with a significant improvement in distance corrected near visual acuity.

What is Eyenovia's financial status as of Q3 2022?

Eyenovia reported a net loss of $7.3 million for Q3 2022 and had $25.3 million in cash and equivalents.

When does Eyenovia plan to meet with the FDA?

Eyenovia plans to meet with the FDA early next year to discuss the regulatory path for MicroLine.

What are Eyenovia's expected milestones for 2023?

Eyenovia anticipates achieving multiple key milestones related to MicroLine and its partnerships in 2023.